Business
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
- Cleveland Clinic conducting Phase 1 trial - SAN JOSE, Calif. and CLEVELAND, Oct. 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"- Cleveland Clinic conducting Phase 1 trial -\n\n\nSAN JOSE, Calif. and CLEVELAND, Oct. 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) (\"Anixa\") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated for preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Anixa has a worldwide, exclusive license to the vaccine technology originating from Cleveland Clinic. \n\n \n \n \n \n \n \n\n \nFunded by the U.S. Department of Defense, the new study is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study will be conducted at Cleveland Clinic and will consist of 18 to 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. During the course of the study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. The study is estimated to be completed in the third quarter of 2022. \n\"As we begin this first-of-its-kind clinical study with our partner, Cleveland Clinic, it is truly an exciting time for Anixa,\" stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. \"Our vaccine has the potential to prevent the development of the most aggressive form of breast cancer – triple-negative breast cancer. We look forward to the prospect of advancing this promising candidate throughout later stage studies.\"\nThe study that is being conducted today is based on pre-clinical work conducted by Cleveland Clinic researchers that was originally published in Nature Medicine. Plans for subsequent trials of Anixa Bioscience's vaccine would involve healthy, cancer-free study participants at high risk for developing breast cancer who have decided to undergo voluntary bilateral mastectomy to lower their risk. Typically, those women carry mutations in the BRCA1 or related genes and are therefore at risk of developing triple-negative breast cancer ...